US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

49.09

-1.4300-2.83%

Post-market: 49.200.1100+0.22%19:59 EDT

Volume:592.57K

Turnover:29.71M

Market Cap:3.50B

PE:-15.77

High:51.11

Open:50.70

Low:49.01

Close:50.52

52wk High:94.90

52wk Low:18.26

Shares:71.31M

Float Shares:54.64M

Volume Ratio:0.80

T/O Rate:1.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1128

EPS(LYR):-2.3852

ROE:-20.21%

ROA:-14.95%

PB:2.58

PE(LYR):-20.58

Loading ...

Overview Company News Filings

How Phase 2b Oral GLP-1 Data and Phase 3 Plans Will Impact Structure Therapeutics (GPCR) Investors

Simply Wall St.

Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.

Structure's experimental obesity pill shows no signs of liver injury

Structure Therapeutics - Aleniglipron Shows up to 16.2% Weight Loss Beyond 36 Weeks in Phase 2B Trial

THOMSON REUTERS

Structure Therapeutics - Aleniglipron Demonstrates 10.4% Discontinuation Rate With Favorable Tolerability

THOMSON REUTERS

Structure Therapeutics - Phase 3 Program for Aleniglipron to Initiate in Q3 2026

THOMSON REUTERS

Structure Therapeutics announces ACCESS trial data published in Nature Medicine

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Analysts’ Top Healthcare Picks: Olema Pharmaceuticals (OLMA), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Press Release: AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

Press Release: Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

Nxera Pharma Spins Out Non-Core GPCR Program in NewCo Licensing and Series A Deal

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Guggenheim

Structure Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Structure Therapeutics Inc - Amends and Restates Sales Agreement With Leerink Partners Llc and Cantor Fitzgerald & Co. on May 7, 2026 - SEC Filing

THOMSON REUTERS

Structure Therapeutics Inc - Increases Atm Shares Offering by $150 Mln to Aggregate $400 Mln - SEC Filing

THOMSON REUTERS

Structure Therapeutics Q1 FY26 net loss widens to $76 million

BRIEF-Structure Therapeutics Inc. Q1 Net Income USD -75.968 Million

Structure Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/GPCR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GPCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":49.09,"timestamp":1787342400000,"preClose":50.52,"halted":0,"volume":592574,"hourTrading":{"tag":"盘后","latestPrice":49.2,"preClose":49.09,"latestTime":"19:59 EDT","volume":44750,"amount":2196926.26,"timestamp":1787356775142,"change":0.11,"changeRate":0.002241,"amplitude":0.010389},"delay":0,"changeRate":-0.028305621536025328,"floatShares":54641899,"shares":71309857,"eps":-3.1128,"marketStatus":"Market Closed","change":-1.43,"latestTime":"08-21 16:00:00 EDT","open":50.7,"high":51.11,"low":49.01,"amount":29714636.859202,"amplitude":0.041568,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.1128,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":50.52,"preHourTrading":{"tag":"盘前","latestPrice":51.2,"preClose":50.52,"latestTime":"09:15 EDT","volume":721,"amount":36627.699087,"timestamp":1787318123448,"change":0.68,"changeRate":0.01346,"amplitude":0.054236},"postHourTrading":{"tag":"盘后","latestPrice":49.2,"preClose":49.09,"latestTime":"19:59 EDT","volume":44750,"amount":2196926.26,"timestamp":1787356775142,"change":0.11,"changeRate":0.002241,"amplitude":0.010389},"volumeRatio":0.8033914747715426,"impliedVol":0.7978,"impliedVolPercentile":0.5777},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","floatShares":54641899,"roa":"-14.95%","roe":"-20.21%","lyrEps":-2.385222,"volumeRatio":0.8033914747715426,"shares":71309857,"dividePrice":0,"high":51.11,"amplitude":0.041568,"preClose":50.52,"low":49.01,"week52Low":18.264,"pbRate":"2.58","week52High":94.9,"institutionHeld":0,"latestPrice":49.09,"eps":-3.1128,"divideRate":0,"volume":592574,"delay":0,"ttmEps":-3.1128,"open":50.7,"prevYearClose":69.55,"prevWeekClose":54.51,"prevMonthClose":48.04,"prevQuarterClose":53.67,"fiveDayClose":54.51,"twentyDayClose":49.12,"sixtyDayClose":39.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GPCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"GPCR","fiscalQuarterEnding":"2026/06","expectedEps":-0.39,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2026-05-07","symbol":"GPCR","fiscalQuarterEnding":"2026/03","expectedEps":-0.39,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.35},{"market":"US","date":"2026-02-26","symbol":"GPCR","fiscalQuarterEnding":"2025/12","expectedEps":-0.35,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-11-06","symbol":"GPCR","fiscalQuarterEnding":"2025/09","expectedEps":-0.36,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.37},{"market":"US","date":"2025-08-06","symbol":"GPCR","fiscalQuarterEnding":"2025/06","expectedEps":-0.28,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.36}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GPCR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GPCR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3529,"buy":0.5882,"hold":0.0588,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5882,"analysts":17,"updateTime":1777348800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GPCR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GPCR","date":"2026-08-21","current":-15.770368,"percent":0.668591,"low":-50.180001,"twenty":-24.436431,"median":-19.854838,"eighty":-10.567565,"high":-5.211405,"avg":-19.432697,"sd":8.246779,"marketCap":3602573975},"quantilePoints":[{"date":"2023-02-03","current":-25.001825,"twenty":-43.272389,"median":-43.272389,"eighty":-32.310051,"marketCap":951294422},{"date":"2023-02-10","current":-22.116999,"twenty":-35.964163,"median":-23.496907,"eighty":-22.21316,"marketCap":841529681},{"date":"2023-02-17","current":-21.285207,"twenty":-24.521021,"median":-22.645883,"eighty":-21.915061,"marketCap":809880847},{"date":"2023-02-24","current":-23.36709,"twenty":-23.715192,"median":-22.645883,"eighty":-21.847749,"marketCap":889094402},{"date":"2023-03-03","current":-25.530709,"twenty":-24.422936,"median":-22.718004,"eighty":-21.972757,"marketCap":971417957},{"date":"2023-03-10","current":-22.636267,"twenty":-24.85566,"median":-22.790125,"eighty":-22.063149,"marketCap":861287334},{"date":"2023-03-17","current":-22.232392,"twenty":-24.422936,"median":-22.70358,"eighty":-22.09392,"marketCap":845920270},{"date":"2023-03-24","current":-21.876596,"twenty":-23.762311,"median":-22.568955,"eighty":-21.891982,"marketCap":832382619},{"date":"2023-03-31","current":-16.960589,"twenty":-23.565181,"median":-22.314128,"eighty":-21.634271,"marketCap":870434396},{"date":"2023-04-06","current":-17.823234,"twenty":-23.376706,"median":-22.232392,"eighty":-21.285207,"marketCap":914706175},{"date":"2023-04-14","current":-17.473898,"twenty":-23.36709,"median":-22.116999,"eighty":-18.643102,"marketCap":896777933},{"date":"2023-04-21","current":-17.210114,"twenty":-23.194,"median":-22.059302,"eighty":-17.623613,"marketCap":883240282},{"date":"2023-04-28","current":-17.815518,"twenty":-23.078607,"median":-21.876596,"eighty":-17.586227,"marketCap":914310203},{"date":"2023-05-05","current":-17.709107,"twenty":-22.982446,"median":-21.689083,"eighty":-17.623613,"marketCap":908849077},{"date":"2023-05-12","current":-17.00755,"twenty":-22.790125,"median":-21.491953,"eighty":-17.586227,"marketCap":956079400},{"date":"2023-05-19","current":-15.32957,"twenty":-22.780509,"median":-20.818827,"eighty":-17.473898,"marketCap":861751761},{"date":"2023-05-26","current":-19.808636,"twenty":-22.761276,"median":-19.808636,"eighty":-17.466769,"marketCap":1113542462},{"date":"2023-06-02","current":-21.830342,"twenty":-22.668962,"median":-20.674586,"eighty":-17.472472,"marketCap":1227192672},{"date":"2023-06-09","current":-23.110075,"twenty":-22.668962,"median":-21.38858,"eighty":-17.563702,"marketCap":1299132872},{"date":"2023-06-16","current":-21.061141,"twenty":-22.668962,"median":-21.491953,"eighty":-17.586212,"marketCap":1183952020},{"date":"2023-06-23","current":-21.782692,"twenty":-22.640113,"median":-21.568882,"eighty":-17.608538,"marketCap":1224514048},{"date":"2023-06-30","current":-27.561913,"twenty":-22.772816,"median":-21.571672,"eighty":-17.623492,"marketCap":1549392931},{"date":"2023-07-07","current":-24.451072,"twenty":-23.059375,"median":-21.612515,"eighty":-17.625039,"marketCap":1374517018},{"date":"2023-07-14","current":-21.428724,"twenty":-23.103781,"median":-21.707815,"eighty":-17.644282,"marketCap":1204615694},{"date":"2023-07-21","current":-23.069233,"twenty":-23.103781,"median":-21.780436,"eighty":-17.700571,"marketCap":1296836908},{"date":"2023-07-28","current":-23.552536,"twenty":-23.333385,"median":-21.782692,"eighty":-17.727736,"marketCap":1324005814},{"date":"2023-08-04","current":-21.592094,"twenty":-23.51737,"median":-21.782692,"eighty":-17.804907,"marketCap":1213799550},{"date":"2023-08-11","current":-19.978813,"twenty":-23.374783,"median":-21.781564,"eighty":-17.817061,"marketCap":1123108978},{"date":"2023-08-18","current":-16.072919,"twenty":-23.333385,"median":-21.735043,"eighty":-17.644282,"marketCap":1053531639},{"date":"2023-08-25","current":-16.66259,"twenty":-23.197654,"median":-21.646551,"eighty":-17.586168,"marketCap":1092182818},{"date":"2023-09-01","current":-16.458249,"twenty":-23.185384,"median":-21.592094,"eighty":-17.468195,"marketCap":1078788845},{"date":"2023-09-08","current":-16.680105,"twenty":-23.150918,"median":-21.568882,"eighty":-17.319402,"marketCap":1093330873},{"date":"2023-09-15","current":-18.326514,"twenty":-23.110075,"median":-21.460338,"eighty":-17.211393,"marketCap":1201248026},{"date":"2023-09-22","current":-19.937893,"twenty":-23.078607,"median":-21.067948,"eighty":-17.309925,"marketCap":1306869070},{"date":"2023-09-29","current":-21.876218,"twenty":-23.069233,"median":-21.012104,"eighty":-17.319402,"marketCap":1433920470},{"date":"2023-10-06","current":-37.165618,"twenty":-23.194,"median":-21.285207,"eighty":-17.395476,"marketCap":2436094784},{"date":"2023-10-13","current":-44.162453,"twenty":-23.552536,"median":-21.525005,"eighty":-17.459473,"marketCap":2894716299},{"date":"2023-10-20","current":-45.222784,"twenty":-23.852048,"median":-21.571672,"eighty":-17.466769,"marketCap":2964217822},{"date":"2023-10-27","current":-47.275909,"twenty":-23.892891,"median":-21.592094,"eighty":-17.469621,"marketCap":3098794020},{"date":"2023-11-03","current":-48.538851,"twenty":-24.328544,"median":-21.646551,"eighty":-17.490333,"marketCap":3181576088},{"date":"2023-11-10","current":-38.273225,"twenty":-24.864943,"median":-21.735043,"eighty":-17.514986,"marketCap":2508695101},{"date":"2023-11-17","current":-27.570058,"twenty":-25.04304,"median":-21.781564,"eighty":-17.543453,"marketCap":2122673903},{"date":"2023-11-24","current":-32.691508,"twenty":-27.365869,"median":-21.782692,"eighty":-17.586168,"marketCap":2516984612},{"date":"2023-12-01","current":-35.337541,"twenty":-28.3175,"median":-21.830342,"eighty":-17.593664,"marketCap":2720707940},{"date":"2023-12-08","current":-37.983573,"twenty":-33.138225,"median":-21.904522,"eighty":-17.623452,"marketCap":2924431267},{"date":"2023-12-15","current":-37.177707,"twenty":-34.105722,"median":-22.049686,"eighty":-17.625039,"marketCap":2862386033},{"date":"2023-12-22","current":-20.939825,"twenty":-34.105722,"median":-22.001606,"eighty":-17.644282,"marketCap":1612198995},{"date":"2023-12-29","current":-23.446258,"twenty":-34.065552,"median":-22.068918,"eighty":-17.684898,"marketCap":1805174329},{"date":"2024-01-05","current":-26.187472,"twenty":-34.000259,"median":-22.102574,"eighty":-17.702705,"marketCap":2016225834},{"date":"2024-01-12","current":-28.789086,"twenty":-33.67371,"median":-22.232392,"eighty":-17.746366,"marketCap":2216529345},{"date":"2024-01-19","current":-27.710368,"twenty":-33.290514,"median":-22.259189,"eighty":-17.804907,"marketCap":2133476670},{"date":"2024-01-26","current":-26.745867,"twenty":-33.138225,"median":-22.283013,"eighty":-17.817061,"marketCap":2059217807},{"date":"2024-02-02","current":-28.598724,"twenty":-32.691508,"median":-22.44298,"eighty":-17.823234,"marketCap":2201872991},{"date":"2024-02-09","current":-29.823387,"twenty":-32.667396,"median":-22.576119,"eighty":-17.835432,"marketCap":2296162205},{"date":"2024-02-16","current":-28.427399,"twenty":-32.293017,"median":-22.636267,"eighty":-17.890184,"marketCap":2188682272},{"date":"2024-02-23","current":-26.035182,"twenty":-31.181303,"median":-22.647193,"eighty":-17.91403,"marketCap":2004500750},{"date":"2024-03-01","current":-25.743294,"twenty":-31.092467,"median":-22.775115,"eighty":-17.959972,"marketCap":1982027673},{"date":"2024-03-08","current":-22.849791,"twenty":-30.933832,"median":-22.849791,"eighty":-18.031985,"marketCap":1759251085},{"date":"2024-03-15","current":-18.291889,"twenty":-29.823387,"median":-22.775115,"eighty":-18.031985,"marketCap":1639319082},{"date":"2024-03-22","current":-22.815466,"twenty":-29.601298,"median":-22.761276,"eighty":-18.070517,"marketCap":2044722039},{"date":"2024-03-28","current":-22.311113,"twenty":-29.398245,"median":-22.645883,"eighty":-18.070517,"marketCap":1999521939},{"date":"2024-04-05","current":-20.434088,"twenty":-29.301795,"median":-22.601624,"eighty":-18.089549,"marketCap":1831303011},{"date":"2024-04-12","current":-20.928042,"twenty":-29.107626,"median":-22.568955,"eighty":-18.098906,"marketCap":1875571150},{"date":"2024-04-19","current":-18.81184,"twenty":-29.061939,"median":-22.455039,"eighty":-18.224405,"marketCap":1685917123},{"date":"2024-04-26","current":-20.267704,"twenty":-28.863962,"median":-22.311113,"eighty":-18.256547,"marketCap":1816391638},{"date":"2024-05-03","current":-20.281918,"twenty":-28.794162,"median":-22.289169,"eighty":-18.270537,"marketCap":1817665530},{"date":"2024-05-10","current":-20.105056,"twenty":-28.789086,"median":-22.270856,"eighty":-18.288305,"marketCap":1801815151},{"date":"2024-05-17","current":-17.123915,"twenty":-28.636796,"median":-22.232392,"eighty":-18.098906,"marketCap":1672681180},{"date":"2024-05-24","current":-18.288418,"twenty":-28.476893,"median":-22.116999,"eighty":-18.062811,"marketCap":1786430959},{"date":"2024-05-31","current":-16.11295,"twenty":-28.435013,"median":-22.068918,"eighty":-17.902107,"marketCap":1573929112},{"date":"2024-06-07","current":-26.55105,"twenty":-28.381712,"median":-22.102574,"eighty":-17.902107,"marketCap":2593533072},{"date":"2024-06-14","current":-24.646705,"twenty":-28.337752,"median":-22.198735,"eighty":-17.932407,"marketCap":2407514791},{"date":"2024-06-21","current":-22.312809,"twenty":-28.3175,"median":-22.24579,"eighty":-17.974375,"marketCap":2179537500},{"date":"2024-06-28","current":-18.680713,"twenty":-28.3175,"median":-22.24579,"eighty":-18.00318,"marketCap":1824750754},{"date":"2024-07-05","current":-17.874111,"twenty":-28.267548,"median":-22.198735,"eighty":-17.932407,"marketCap":1745961056},{"date":"2024-07-12","current":-20.408464,"twenty":-28.068249,"median":-22.08815,"eighty":-17.932407,"marketCap":1993519219},{"date":"2024-07-15","current":-20.943017,"twenty":-28.006064,"median":-22.078534,"eighty":-17.941595,"marketCap":2045734877},{"date":"2024-08-02","current":-17.387286,"twenty":-27.943879,"median":-22.068918,"eighty":-17.908069,"marketCap":1698407510},{"date":"2024-08-09","current":-16.461364,"twenty":-27.802578,"median":-21.942986,"eighty":-17.823234,"marketCap":1607962532},{"date":"2024-08-16","current":-20.792004,"twenty":-27.780694,"median":-21.876596,"eighty":-17.821691,"marketCap":2088244945},{"date":"2024-08-23","current":-22.295452,"twenty":-27.74971,"median":-21.929398,"eighty":-17.823234,"marketCap":2239243758},{"date":"2024-08-30","current":-21.822777,"twenty":-27.716713,"median":-21.953525,"eighty":-17.863936,"marketCap":2191770646},{"date":"2024-09-06","current":-21.851252,"twenty":-27.691332,"median":-21.926349,"eighty":-17.874111,"marketCap":2194630472},{"date":"2024-09-13","current":-22.944669,"twenty":-27.671026,"median":-21.901472,"eighty":-17.880178,"marketCap":2304447790},{"date":"2024-09-20","current":-22.067657,"twenty":-27.608415,"median":-21.926349,"eighty":-17.902107,"marketCap":2216365150},{"date":"2024-09-27","current":-23.650834,"twenty":-27.565171,"median":-22.001606,"eighty":-17.941595,"marketCap":2375371475},{"date":"2024-10-04","current":-24.083644,"twenty":-27.536769,"median":-22.068918,"eighty":-18.000093,"marketCap":2418840830},{"date":"2024-10-11","current":-22.130301,"twenty":-27.481934,"median":-22.12365,"eighty":-18.029927,"marketCap":2222656767},{"date":"2024-10-18","current":-22.563112,"twenty":-27.163394,"median":-22.116999,"eighty":-18.055104,"marketCap":2266126122},{"date":"2024-10-25","current":-21.333018,"twenty":-26.967956,"median":-22.11226,"eighty":-18.070517,"marketCap":2142581639},{"date":"2024-10-31","current":-21.560813,"twenty":-26.932422,"median":-22.097835,"eighty":-18.080033,"marketCap":2165460247},{"date":"2024-11-08","current":-21.839862,"twenty":-26.875803,"median":-22.107521,"eighty":-18.096607,"marketCap":2193486542},{"date":"2024-11-15","current":-19.500107,"twenty":-26.820843,"median":-22.068288,"eighty":-18.16223,"marketCap":2155736838},{"date":"2024-11-22","current":-15.573182,"twenty":-26.740791,"median":-22.039183,"eighty":-18.047398,"marketCap":1721615252},{"date":"2024-11-29","current":-17.170432,"twenty":-26.702879,"median":-21.932448,"eighty":-17.923218,"marketCap":1898191276},{"date":"2024-12-06","current":-16.181125,"twenty":-26.575564,"median":-21.883856,"eighty":-17.833409,"marketCap":1788823393},{"date":"2024-12-13","current":-16.424567,"twenty":-26.524021,"median":-21.851252,"eighty":-17.817061,"marketCap":1815735909},{"date":"2024-12-20","current":-15.523314,"twenty":-26.386717,"median":-21.835102,"eighty":-17.715324,"marketCap":1716102339},{"date":"2024-12-27","current":-15.30059,"twenty":-26.269962,"median":-21.822777,"eighty":-17.687076,"marketCap":1691480250},{"date":"2025-01-03","current":-14.601342,"twenty":-26.20397,"median":-21.78933,"eighty":-17.625803,"marketCap":1614178343},{"date":"2025-01-10","current":-14.005686,"twenty":-26.17605,"median":-21.782692,"eighty":-17.604018,"marketCap":1548328570},{"date":"2025-01-17","current":-13.974608,"twenty":-26.160821,"median":-21.780436,"eighty":-17.514986,"marketCap":1544892930},{"date":"2025-01-24","current":-14.482211,"twenty":-26.10752,"median":-21.737354,"eighty":-17.469621,"marketCap":1601008389},{"date":"2025-01-31","current":-15.7046,"twenty":-26.035182,"median":-21.700984,"eighty":-17.381485,"marketCap":1736143575},{"date":"2025-02-07","current":-15.549212,"twenty":-26.032644,"median":-21.680405,"eighty":-17.295679,"marketCap":1718965373},{"date":"2025-02-14","current":-12.622728,"twenty":-25.9819,"median":-21.605123,"eighty":-17.234446,"marketCap":1395442576},{"date":"2025-02-21","current":-12.115125,"twenty":-25.903236,"median":-21.581883,"eighty":-17.21037,"marketCap":1339327118},{"date":"2025-02-28","current":-11.819887,"twenty":-25.84482,"median":-21.567582,"eighty":-17.171628,"marketCap":1306688535},{"date":"2025-03-07","current":-11.01217,"twenty":-25.735679,"median":-21.559435,"eighty":-17.124089,"marketCap":1349277189},{"date":"2025-03-14","current":-9.547313,"twenty":-25.689992,"median":-21.491953,"eighty":-17.045645,"marketCap":1169794078},{"date":"2025-03-21","current":-10.235281,"twenty":-25.609403,"median":-21.417887,"eighty":-16.960589,"marketCap":1254088063},{"date":"2025-03-28","current":-9.33203,"twenty":-25.527539,"median":-21.321628,"eighty":-16.93886,"marketCap":1143416369},{"date":"2025-04-04","current":-7.64253,"twenty":-25.480594,"median":-21.202701,"eighty":-16.831205,"marketCap":936408691},{"date":"2025-04-11","current":-7.043483,"twenty":-25.340669,"median":-21.061141,"eighty":-16.666093,"marketCap":863009847},{"date":"2025-04-17","current":-8.672143,"twenty":-25.329214,"median":-21.042579,"eighty":-16.563339,"marketCap":1062562954},{"date":"2025-04-25","current":-11.068331,"twenty":-25.25285,"median":-20.951128,"eighty":-16.426861,"marketCap":1356158331},{"date":"2025-05-02","current":-12.790591,"twenty":-25.171712,"median":-20.933479,"eighty":-16.305436,"marketCap":1567180008},{"date":"2025-05-09","current":-12.551909,"twenty":-25.070517,"median":-20.891345,"eighty":-16.181125,"marketCap":1537935156},{"date":"2025-05-16","current":-9.774326,"twenty":-25.068859,"median":-20.829252,"eighty":-16.056814,"marketCap":1400885752},{"date":"2025-05-23","current":-9.895696,"twenty":-25.0453,"median":-20.693431,"eighty":-15.839386,"marketCap":1418280862},{"date":"2025-05-30","current":-9.000467,"twenty":-25.01052,"median":-20.672234,"eighty":-15.745511,"marketCap":1289973912},{"date":"2025-06-06","current":-8.619091,"twenty":-25.001825,"median":-20.550917,"eighty":-15.544032,"marketCap":1235314001},{"date":"2025-06-13","current":-8.920177,"twenty":-24.996225,"median":-20.487391,"eighty":-15.387426,"marketCap":1278466562},{"date":"2025-06-20","current":-8.679308,"twenty":-24.952868,"median":-20.449033,"eighty":-14.973238,"marketCap":1243944513},{"date":"2025-06-27","current":-8.462526,"twenty":-24.918331,"median":-20.434088,"eighty":-14.66039,"marketCap":1212874668},{"date":"2025-07-03","current":-8.175491,"twenty":-24.875783,"median":-20.408464,"eighty":-14.607558,"marketCap":1171735893},{"date":"2025-07-11","current":-7.587369,"twenty":-24.818526,"median":-20.385744,"eighty":-14.451133,"marketCap":1087444556},{"date":"2025-07-18","current":-7.840282,"twenty":-24.807686,"median":-20.281918,"eighty":-14.123781,"marketCap":1123692707},{"date":"2025-07-25","current":-7.334457,"twenty":-24.781668,"median":-20.180483,"eighty":-13.987039,"marketCap":1051196404},{"date":"2025-08-01","current":-7.145777,"twenty":-24.722332,"median":-20.085721,"eighty":-13.108576,"marketCap":1024154132},{"date":"2025-08-08","current":-5.211405,"twenty":-24.651853,"median":-19.971704,"eighty":-12.812535,"marketCap":932580977},{"date":"2025-08-15","current":-5.964179,"twenty":-24.61951,"median":-19.937893,"eighty":-12.626872,"marketCap":1067289809},{"date":"2025-08-22","current":-6.234546,"twenty":-24.540145,"median":-19.829477,"eighty":-12.490132,"marketCap":1115672078},{"date":"2025-08-29","current":-6.160517,"twenty":-24.4698,"median":-19.66456,"eighty":-12.119485,"marketCap":1102424552},{"date":"2025-09-05","current":-6.360074,"twenty":-24.389808,"median":-19.576169,"eighty":-11.77845,"marketCap":1138135274},{"date":"2025-09-12","current":-6.720564,"twenty":-24.139365,"median":-19.456275,"eighty":-11.057099,"marketCap":1202644966},{"date":"2025-09-19","current":-7.47695,"twenty":-24.11098,"median":-19.134734,"eighty":-10.896967,"marketCap":1338000122},{"date":"2025-09-26","current":-8.043434,"twenty":-24.072254,"median":-19.014985,"eighty":-10.567565,"marketCap":1439372495},{"date":"2025-10-03","current":-8.568076,"twenty":-24.020356,"median":-18.941828,"eighty":-10.325716,"marketCap":1533257136},{"date":"2025-10-10","current":-9.833009,"twenty":-23.986828,"median":-18.81071,"eighty":-10.186609,"marketCap":1759617036},{"date":"2025-10-17","current":-8.87063,"twenty":-23.947347,"median":-18.74276,"eighty":-9.917033,"marketCap":1587399198},{"date":"2025-10-24","current":-8.548764,"twenty":-23.914099,"median":-18.661907,"eighty":-9.852324,"marketCap":1529801259},{"date":"2025-10-31","current":-10.370526,"twenty":-23.886602,"median":-18.351918,"eighty":-9.836476,"marketCap":1855805594},{"date":"2025-11-07","current":-10.772858,"twenty":-23.868757,"median":-18.327399,"eighty":-9.850579,"marketCap":1927803018},{"date":"2025-11-14","current":-10.08006,"twenty":-23.852048,"median":-18.288418,"eighty":-9.817863,"marketCap":2123717400},{"date":"2025-11-21","current":-9.889979,"twenty":-23.841601,"median":-18.256152,"eighty":-9.836476,"marketCap":2083670157},{"date":"2025-11-28","current":-10.313341,"twenty":-23.799814,"median":-18.097181,"eighty":-9.841018,"marketCap":2172866288},{"date":"2025-12-05","current":-9.460856,"twenty":-23.776121,"median":-18.070517,"eighty":-9.814076,"marketCap":1993260474},{"date":"2025-12-12","current":-19.422835,"twenty":-23.650834,"median":-18.082412,"eighty":-9.833009,"marketCap":4092100041},{"date":"2025-12-19","current":-17.985707,"twenty":-23.62393,"median":-18.070517,"eighty":-9.841018,"marketCap":3789318618},{"date":"2025-12-26","current":-22.869735,"twenty":-23.621272,"median":-18.100056,"eighty":-9.848479,"marketCap":4818310220},{"date":"2026-01-02","current":-22.823793,"twenty":-23.615623,"median":-18.255492,"eighty":-9.851048,"marketCap":4808630734},{"date":"2026-01-09","current":-21.980412,"twenty":-23.576442,"median":-18.281194,"eighty":-9.851517,"marketCap":4630943013},{"date":"2026-01-16","current":-27.900487,"twenty":-23.621936,"median":-18.326514,"eighty":-9.853937,"marketCap":5878214018},{"date":"2026-01-23","current":-30.148409,"twenty":-23.790337,"median":-18.349084,"eighty":-9.86147,"marketCap":6351817477},{"date":"2026-01-30","current":-28.599475,"twenty":-23.883185,"median":-18.63625,"eighty":-9.874048,"marketCap":6025480495},{"date":"2026-02-06","current":-24.024872,"twenty":-24.012922,"median":-18.680713,"eighty":-9.881446,"marketCap":5061680173},{"date":"2026-02-13","current":-23.64092,"twenty":-24.104146,"median":-18.735704,"eighty":-9.886523,"marketCap":4980787319},{"date":"2026-02-20","current":-22.141212,"twenty":-24.072254,"median":-18.787312,"eighty":-9.891122,"marketCap":4664821216},{"date":"2026-02-27","current":-21.248606,"twenty":-24.026331,"median":-18.905431,"eighty":-9.903769,"marketCap":4476762617},{"date":"2026-03-06","current":-29.951815,"twenty":-24.389808,"median":-18.958825,"eighty":-9.939515,"marketCap":4229256176},{"date":"2026-03-13","current":-27.383083,"twenty":-24.63457,"median":-19.091174,"eighty":-9.953915,"marketCap":3866546098},{"date":"2026-03-20","current":-25.316057,"twenty":-24.813106,"median":-19.247915,"eighty":-9.965451,"marketCap":3574677833},{"date":"2026-03-27","current":-23.178791,"twenty":-24.786548,"median":-19.412443,"eighty":-10.00684,"marketCap":3272891714},{"date":"2026-04-02","current":-25.170562,"twenty":-24.791427,"median":-19.500107,"eighty":-10.024679,"marketCap":3554133708},{"date":"2026-04-10","current":-27.664038,"twenty":-24.924896,"median":-19.588971,"eighty":-10.070397,"marketCap":3906217513},{"date":"2026-04-17","current":-26.841241,"twenty":-25.001825,"median":-19.762743,"eighty":-10.08006,"marketCap":3790036942},{"date":"2026-04-24","current":-23.59019,"twenty":-25.001825,"median":-19.852578,"eighty":-10.16646,"marketCap":3330982000},{"date":"2026-05-01","current":-20.863024,"twenty":-25.001825,"median":-19.937893,"eighty":-10.183801,"marketCap":2945900742},{"date":"2026-05-08","current":-19.705365,"twenty":-24.994825,"median":-19.961493,"eighty":-10.197841,"marketCap":2782437010},{"date":"2026-05-15","current":-16.62279,"twenty":-24.933886,"median":-19.910742,"eighty":-10.230435,"marketCap":2831476129},{"date":"2026-05-22","current":-16.184689,"twenty":-24.924896,"median":-19.829477,"eighty":-10.235281,"marketCap":2756851382},{"date":"2026-05-29","current":-20.218762,"twenty":-24.916142,"median":-19.78569,"eighty":-10.28472,"marketCap":2854929621},{"date":"2026-06-05","current":-19.660066,"twenty":-24.837612,"median":-19.705365,"eighty":-10.310089,"marketCap":2776040603},{"date":"2026-06-12","current":-21.794185,"twenty":-24.818526,"median":-19.734054,"eighty":-10.313341,"marketCap":3077382440},{"date":"2026-06-18","current":-18.776621,"twenty":-24.802267,"median":-19.684963,"eighty":-10.332349,"marketCap":3198353220},{"date":"2026-06-26","current":-20.13271,"twenty":-24.776789,"median":-19.66456,"eighty":-10.358393,"marketCap":3429345397},{"date":"2026-07-02","current":-21.747499,"twenty":-24.722332,"median":-19.762743,"eighty":-10.368595,"marketCap":3704403773},{"date":"2026-07-10","current":-23.007619,"twenty":-24.651853,"median":-19.829477,"eighty":-10.39842,"marketCap":3919048812},{"date":"2026-07-17","current":-19.206397,"twenty":-24.633491,"median":-19.854838,"eighty":-10.468301,"marketCap":3271559971},{"date":"2026-07-24","current":-21.196718,"twenty":-24.602614,"median":-19.924318,"eighty":-10.512193,"marketCap":3610585412},{"date":"2026-07-31","current":-20.641765,"twenty":-24.584569,"median":-19.948142,"eighty":-10.52082,"marketCap":3516056306},{"date":"2026-08-07","current":-21.956128,"twenty":-24.559431,"median":-19.978813,"eighty":-10.545017,"marketCap":3739941031},{"date":"2026-08-14","current":-18.156488,"twenty":-24.476043,"median":-19.948142,"eighty":-10.550775,"marketCap":3900649177},{"date":"2026-08-21","current":-16.769027,"twenty":-24.436431,"median":-19.854838,"eighty":-10.567565,"marketCap":3602573975}],"updateTime":1787444242321},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GPCR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2641483261","title":"How Phase 2b Oral GLP-1 Data and Phase 3 Plans Will Impact Structure Therapeutics (GPCR) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641483261","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641483261?lang=en_us&edition=fundamental","pubTime":"2026-06-08 16:14","pubTimestamp":1780906459,"startTime":"0","endTime":"0","summary":"Structure Therapeutics recently published Phase 2b ACCESS trial results for its oral GLP-1 agonist aleniglipron in Nature Medicine and presented the data at the American Diabetes Association’s 86th Scientific Sessions, showing statistically significant weight loss and improvements in multiple cardiovascular risk markers in people with obesity or overweight.\nAn interesting insight from the open-label extension is that many participants who interrupted dosing could restart or up-titrate...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/how-phase-2b-oral-glp-1-data-and-phase-3-plans-will-impact-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/how-phase-2b-oral-glp-1-data-and-phase-3-plans-will-impact-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GLP","GPCR","BK4590","BK4007","ISBC","BK4211","BK4599","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127457","title":"Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127457","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641127457?lang=en_us&edition=fundamental","pubTime":"2026-06-07 02:53","pubTimestamp":1780771980,"startTime":"0","endTime":"0","summary":"These experimental drugs could be better than Zepbound and Wegovy.This includes retatrutide, the GLP-1 injection that helped people lose 28% of their body weight in clinical trials. Wegovy is the first GLP-1 approved for weight loss, but there are several new GLP-1 drugs in development.One of the most anticipated new weight-loss drugs also helped people struggling with common obesity-related conditions like sleep apnea.The drug is retatrutide, which pairs GLP-1, GIP and glucagon in a powerful combination that produces more weight loss than any other therapy. It's currently in Phase 3 trials, and Wall Street expects Eli Lilly's  once-weekly drug to launch in the U.S. next year if it's approved by the Food and Drug Administration.That includes fewer doses, and that's why Pfizer  is working on a GLP-1 shot that could be taken once a month. Right now, the available medications have to be dosed much more frequently. The Wegovy and Foundayo pills have to be taken daily, and the standard dosi","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109391861.USD","LU2602419157.SGD","BK4532","LU1291159041.SGD","IE0004445239.USD","LU1868836757.USD","LU0133085943.USD","LU2552382058.USD","IE0004445015.USD","LU0354030438.USD","IE00BK4W5L77.USD","BK4585","LU2491050154.USD","LU0823434583.USD","LU2896262040.SGD","ELIL","LU0882574139.USD","LU2089984988.USD","LU2357305700.SGD","LU0198837287.USD","LU1883839398.USD","LU0943347566.SGD","LU1093756325.SGD","LLYX","LU1983299246.USD","LU2552382215.SGD","SG9999017495.SGD","LU0689472784.USD","LU0820561909.HKD","LU1868836591.USD","SGXZ51526630.SGD","IE00BBT3K403.USD","BK4550","LU1066051498.USD","LU2750360997.AUD","SG9999002232.USD","SG9999015986.USD","LU1061106388.HKD","LU2361044949.HKD","LU2746668974.SGD","LU1868837136.USD","LU1232071149.USD","LU2264538146.SGD","LU2456880835.USD","LU0225284248.USD","SGXZ81514606.USD","LU0316494557.USD","LU0256863902.USD","AZNH","IE00B775H168.HKD","LU1551013425.SGD","LU2237443382.USD","LU2756315318.SGD","LU0787776722.HKD","LU0466842654.USD","LU0823416689.USD","NVOH","SG9999001176.USD","LU0354030511.USD","BK4588","LU2023250504.SGD","LU2491049909.HKD","IE00BLSP4452.SGD","IE0001KFT4U8.USD","IE00BJJMRZ35.SGD","IE00BZ1G4Q59.USD","LU2361044865.SGD","SG9999013999.USD","LU2491050071.SGD","LU2468319806.SGD","IE00BKDWB100.SGD","IE0002141913.USD","LLYZ","LU2462157665.USD","LU1023059063.AUD","LU1720051017.SGD","LU2089284900.SGD","IE00BKPKM429.USD","IE00B7KXQ091.USD","LU2552382132.HKD","IE00BLSP4239.USD","IE00BN29S564.USD","LU0006306889.USD","LU2028103732.USD","SG9999015945.SGD","LU1804176565.USD","IE00BKVL7J92.USD","LU1145028129.USD","LU2361045086.USD","LU1988902786.USD","LU1623119135.USD","LU2324357040.USD","LU2360106947.USD","IE00BFTCPJ56.SGD","LU0266013472.USD","LU0289739699.SGD","LU0320765059.SGD","LU1989771016.USD","LU2271345857.HKD","LU1629891620.HKD","IE00B3T34201.USD","LU0672654240.SGD","PFE","GPCR","LU0094547139.USD","LU0256863811.USD","LU0106261372.USD","LU0306806265.USD","LU0306807586.USD","LU1064131342.USD","LU2461242641.AUD","LU2236285917.USD","SG9999003800.SGD","LU0114720955.EUR","LU1057294990.SGD","IE00B19Z3581.USD","LU2089283258.USD","LLII","LU0456855351.SGD","IE00BK4W5M84.HKD","BK4533","LU2237443465.HKD","LU0683600562.USD","GB00BDT5M118.USD","LU2168564065.EUR","IE00BJJMRY28.SGD","LU2106854487.HKD","LU1066053197.SGD","IE000M9KFDE8.USD","LU0432979614.USD","LU0471298777.SGD","LU2168563687.JPY","SGXZ57979304.SGD","LU0471298694.HKD","LU0097036916.USD","LU0708995401.HKD","LU2746668461.USD","LU1868836914.USD","LU1814569148.SGD","LU0203201768.USD","LU0158827948.USD","IE0005OL40V9.USD","LU0385154629.USD","LU1267930730.SGD","LU0238689110.USD","LU1551013342.USD","LU0353189763.USD","IE00BWXC8680.SGD","LU1127390331.HKD","BK4599","LU0823434740.USD","BK4007","LU2168564222.USD","LU2237443978.SGD","LU0122379950.USD","LU0225283273.USD","LU1323610961.USD","IE00BJT1NW94.SGD","LU1712237335.SGD","LU1868837300.USD","LU2237443895.HKD","LU1366192091.USD","LU0154236417.USD","LU0868494617.USD","LU2237443549.SGD","SGXZ31699556.SGD","LU1720051108.HKD","LU0210536198.USD","SG9999015978.USD","IE00BJJMRX11.SGD","LU1093756168.USD","LU0964807845.USD","LU1829250122.USD","LU2471134879.HKD","LU0225771236.USD","LLY","LU1069344957.HKD","LU2111349929.HKD","IE00B4JS1V06.HKD","SG9999002224.SGD","BK4592","IE00B1BXHZ80.USD","LU0058720904.USD","LU1974910355.USD","LU0109394709.USD","LU0889565916.HKD","NVOX","LU2087625088.SGD","AZN","IE00B1XK9C88.USD","BK4516","IE00BJLML261.HKD","LU1894683348.USD","LU2756315664.SGD","SG9999014880.SGD","SG9999014898.SGD","IE00BFSS8Q28.SGD","SG9999015952.SGD","SGXZ99366536.SGD","IE00B4R5TH58.HKD","IE00BFSS7M15.SGD","LU1548497426.USD","LU0321505868.SGD","LU2237443622.USD","LU0323591593.USD","LU2213496289.HKD","LU1894683264.USD","LU2265009873.SGD","SG9999014906.USD","SG9999018865.SGD","BK4581","LU0417517546.SGD","LU2471134796.USD","LU0096364046.USD","LU2108987350.USD","SG9999014914.USD","IE00B19Z3B42.SGD","IE0002270589.USD","LU0158827781.USD","LU2750360641.GBP","BK4534","NVO","SG9999011175.SGD","BK4568","SG9999001176.SGD","LU2471134523.USD","LU2237438978.USD","LU0321505439.SGD","LU2023251221.USD","LU0353189680.USD","LU2211815571.USD","LU2596442595.SGD","LU2417539215.USD","LU0170899867.USD","LU0820562030.AUD","LU0640476718.USD","LU1035775433.USD","LU0320765992.SGD","LU0820561818.USD","LU2063271972.USD","LU2168564149.EUR","LU0234572021.USD","SG9999018857.SGD","LU2023250330.USD","LU2471134952.CNY","IE0009355771.USD","LU0079474960.USD","LU0061475181.USD","LU0985481810.HKD","IE00B2B36J28.USD","LU0786609619.USD","LU2112291526.USD","LU1280957306.USD","ELIS","LU0203202063.USD","LU2168564495.EUR","LU1917777945.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641288811","title":"Structure's experimental obesity pill shows no signs of liver injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2641288811","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641288811?lang=en_us&edition=fundamental","pubTime":"2026-06-06 05:14","pubTimestamp":1780694084,"startTime":"0","endTime":"0","summary":"Structure's experimental obesity pill shows no signs of liver injuryBy Sriparna RoyJune 5 (Reuters) - Structure Therapeutics GPCR.O said on Friday its experimental GLP-1 obesity pill did not show any ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nL4N42D1M3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641147769","title":"Structure Therapeutics - Aleniglipron Shows up to 16.2% Weight Loss Beyond 36 Weeks in Phase 2B Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2641147769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641147769?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:17","pubTimestamp":1780690661,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D0AX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641147766","title":"Structure Therapeutics - Aleniglipron Demonstrates 10.4% Discontinuation Rate With Favorable Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2641147766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641147766?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:17","pubTimestamp":1780690661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D0AX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641014775","title":"Structure Therapeutics - Phase 3 Program for Aleniglipron to Initiate in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2641014775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641014775?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:17","pubTimestamp":1780690661,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D0AX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","BK4007","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641147060","title":"Structure Therapeutics announces ACCESS trial data published in Nature Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2641147060","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641147060?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:10","pubTimestamp":1780690253,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) announced a publication in Nature Medicine detailing results from the Phase 2b ACCESS clinical trial of aleniglipron ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-announces-access-trial-data-published-in-nature-medicine-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-announces-access-trial-data-published-in-nature-medicine-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LENZ","BK4599","GPCR","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641472861","title":"Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2641472861","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641472861?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:05","pubTimestamp":1780689900,"startTime":"0","endTime":"0","summary":"Publication presented concurrently with oral presentation at American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecul","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307607/0/en/Structure-Therapeutics-Announces-Publication-in-Nature-Medicine-Highlighting-Phase-2b-ACCESS-Program-of-Aleniglipron-for-Obesity.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4599","GPCR","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638400805","title":"Structure Therapeutics Announces Participation in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2638400805","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638400805?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:05","pubTimestamp":1779825900,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, May  26, 2026  (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3301451/0/en/Structure-Therapeutics-Announces-Participation-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","BK4539","GPCR","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635324933","title":"Analysts’ Top Healthcare Picks: Olema Pharmaceuticals (OLMA), Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635324933","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635324933?lang=en_us&edition=fundamental","pubTime":"2026-05-13 01:00","pubTimestamp":1778605232,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Olema Pharmaceuticals (OLMA), Structure Therapeutics...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-olema-pharmaceuticals-olma-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-olema-pharmaceuticals-olma-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","LABU","LU0029874061.USD","HCSG","LU0128526141.USD","BK4139","BK4581","OLMA","BK4585","BK4137","XBI","BK4505","BK4599","BK4588","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634237850","title":"Press Release: AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635","url":"https://stock-news.laohu8.com/highlight/detail?id=2634237850","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634237850?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529900,"startTime":"0","endTime":"0","summary":"--  ABCL635 demonstrated a favorable tolerability profile, with no observed. liver toxicity, and achieved potent and sustained reductions in. \"We are excited to share interim Phase 1 data that show ABCL635 achieved robust NK3R target engagement at doses that were well-tolerated in healthy volunteers and a pharmacokinetic profile that may support a once monthly dosing regimen. We look forward to the efficacy readout from the Phase 2 data in Q3, which we believe will be highly de-risking for the program,\" said Carl Hansen, Ph.D., founder and CEO of AbCellera. \"Through 2026 we are focused on delivering data readouts for our clinical programs, advancing ABCL688 and ABCL386 into IND-enabling studies, and selecting at least one additional development candidate. We continue to maintain our strong cash position, ending the quarter with approximately $655 million dollars in available liquidity to execute on our strategy.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4007","GPCR","ABCL","BK4121","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634547232","title":"Press Release: Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2634547232","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634547232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529660,"startTime":"0","endTime":"0","summary":"Compelling Phase 1 Data for SEP-631  in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria  in Second Half of 2026. Phase 1 Clinical Trial Initiated for SEP-479, Oral Small Molecule PTH1R Agonist for Hypoparathyroidism. Cash Position of $522.1 Million Expected to Support Operating Plans at Least into 2029. \"In the first quarter, we continued to make meaningful progress across our pipeline, highlighted by positive Phase 1 clinical results for SEP-631 and the initiation of our Phase 1 clinical trial for SEP-479,\" said Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna. \"These advances further validate our Native Complex Platform and its ability to efficiently generate differentiated oral small molecules against historically challenging GPCR targets. As our clinical programs continue to advance, we believe Septerna is increasingly well positioned to unlock the broad therapeutic potential of GPCR-targeted medicines for pa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","SEPN","BK4022","BK4097","BK4007","R","BK4232","GPCR","BK4599","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634036264","title":"Nxera Pharma Spins Out Non-Core GPCR Program in NewCo Licensing and Series A Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2634036264","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634036264?lang=en_us&edition=fundamental","pubTime":"2026-05-11 15:17","pubTimestamp":1778483853,"startTime":"0","endTime":"0","summary":"Sosei Group ( ($JP:4565) ) has provided an update. Nxera Pharma has entered an out-licensing and investment agreement with a newly formed company t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nxera-pharma-spins-out-non-core-gpcr-program-in-newco-licensing-and-series-a-deal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nxera-pharma-spins-out-non-core-gpcr-program-in-newco-licensing-and-series-a-deal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633045323","title":"Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2633045323","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633045323?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:36","pubTimestamp":1778240192,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Seamus Fernandez from Guggenheim maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, with a pric...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/structure-therapeutics-inc-sponsored-adr-gpcr-receives-a-buy-from-guggenheim-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/structure-therapeutics-inc-sponsored-adr-gpcr-receives-a-buy-from-guggenheim-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","BK4007","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633701103","title":"Structure Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633701103","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633701103?lang=en_us&edition=fundamental","pubTime":"2026-05-08 06:39","pubTimestamp":1778193553,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryStructure Therapeutics Inc GPCR.OQ reported a quarterly adjusted loss of 35 cents per share for the quarter ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K3KT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633543170","title":"Structure Therapeutics Inc - Amends and Restates Sales Agreement With Leerink Partners Llc and Cantor Fitzgerald & Co. on May 7, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633543170","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633543170?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:15","pubTimestamp":1778188555,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K1ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","BK4007","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633217068","title":"Structure Therapeutics Inc - Increases Atm Shares Offering by $150 Mln to Aggregate $400 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633217068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633217068?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:15","pubTimestamp":1778188555,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K1ML:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","BK4007","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633174569","title":"Structure Therapeutics Q1 FY26 net loss widens to $76 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633174569","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633174569?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:26","pubTimestamp":1778185574,"startTime":"0","endTime":"0","summary":"Structure Therapeutics posted a Q1 net loss of $76 million, widening from $46.8 million a year earlier.R&D expense climbed to $66.5 million from $42.9 million, while G&A costs rose to $22.9 million from $13.4 million.Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026, with runway expected through end-2028.Reported Phase 2 ACCESS II results for oral GLP-1 agonist aleniglipron showing placebo-adjusted mean weight loss of 16.3% at 180 mg and 16.0% at 240 mg at 44 weeks.Phase 3 initiation for aleniglipron remains on track for Q3 2026 following positive end-of-Phase 2 FDA feedback, with additional ACCESS OLE data due in Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics In","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL6hf2sK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633079176","title":"BRIEF-Structure Therapeutics Inc. Q1 Net Income USD -75.968 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633079176","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633079176?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:05","pubTimestamp":1778184359,"startTime":"0","endTime":"0","summary":"BRIEF-Structure Therapeutics Inc. Q1 Net Income USD -75.968 Million\n\n\nMay 07 (Reuters) - Structure Therapeutics Inc. Q1 operating expenses USD 89.379 million.\n\nQ1 income from operations USD -89.379 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXBC42AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633963108","title":"Structure Therapeutics Inc  expected to post a loss of 35 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633963108","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633963108?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:02","pubTimestamp":1777924957,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc  expected to post a loss of35cents a share - Earnings Preview Structure Therapeutics Inc GPCR.OQ GPCR.O is expected to  show no change in quarterly revenue when it reports  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H23R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":95,"code":"91000000","status":"200"}]}}